Good news for CB1 receptors: endogenous agonists are in the right place
- 29 January 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (2), 179-181
- https://doi.org/10.1038/sj.bjp.0707566
Abstract
Endocannabinoids are endogenous ligands of brain-type (CB1) and spleen-type (CB2) cannabinoid receptors. N-Arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoylglycerol (2-AG) are prototype members of the fatty acid amides and the monoacylglycerols, two groups of endocannabinoids. Unlike CB1, CB2 receptors do not reside within 'caveolae', specialized membrane microdomains that are well-known modulators of the activity of a number of G protein-coupled receptors. In this issue of the British Journal of Pharmacology, Rimmerman and coworkers demonstrate that 2-AG is entirely localized in the caveolae of dorsal root ganglion cells, where also part of AEA (approximately 30%) can be detected. However, most of AEA (approximately 70%) was detected in non-caveolae fractions, that is where CB2 receptors are localized. The different interaction of AEA and 2-AG with membrane microdomains might have significant implications for endocannabinoid-dependent autocrine and/or retrograde-paracrine signalling pathways. It also raises an important question about the structural determinants responsible for a different localization of two apparently similar endocannabinoids within lipid bilayers.Keywords
This publication has 15 references indexed in Scilit:
- Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell lineBritish Journal of Pharmacology, 2008
- Effect of Lipid Rafts on Cb2 Receptor Signaling and 2-Arachidonoyl-Glycerol Metabolism in Human Immune CellsThe Journal of Immunology, 2006
- The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation through a Lipid Raft-Mediated MechanismMolecular Pharmacology, 2006
- Partial QSAR Analysis of Some Selected Natural Inhibitors of FAAH Suggests a Working Hypothesis for the Development of Endocannabinoid- Based DrugsCurrent Drug Targets-CNS & Neurological Disorders, 2005
- Lipids, lipid rafts and caveolae: Their importance for GPCR signaling and their centrality to the endocannabinoid systemLife Sciences, 2005
- Lipid Rafts Control Signaling of Type-1 Cannabinoid Receptors in Neuronal CellsJournal of Biological Chemistry, 2005
- Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosisHepatology, 2003
- The molecular logic of endocannabinoid signallingNature Reviews Neuroscience, 2003
- Conformational Memories and the Endocannabinoid Binding Site at the Cannabinoid CB1 ReceptorJournal of Medicinal Chemistry, 2002
- Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 ReceptorPublished by Elsevier BV ,2000